Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
212Pb-RMX-VH-PKM
- Development stage
- Preclinical
- Lead developer
- Radiomedix
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
212Pb-RMX-VH-PKM is a second-generation radiopharmaceutical and targeted alpha therapy (TAT) agent currently in preclinical development for the treatment of solid tumors, specifically pancreatic ductal adenocarcinoma (PDAC). Co-developed by RadioMedix and Vect-Horus, the conjugate consists of a DOTAM-modified peptide (RMX-VH) that targets the low-density lipoprotein receptor (LDLR), which is frequently overexpressed in various cancers. The therapeutic payload is Lead-212 (212Pb), an alpha-emitting radioisotope that delivers high-energy radiation to induce double-strand DNA breaks in target cells. The "PKM" designation refers to a second-generation modification intended to optimize the conjugate's pharmacokinetic profile, building upon the first-generation 212Pb-RMX-VH compound.
- Other names
- Lead-212 RMX-VH-PKMLead212 RMX-VH-PKMLead 212 RMX-VH-PKM
02
Targets
LDLR (Low-density lipoprotein receptor)
Beyond the preview
Go deeper on 212Pb-RMX-VH-PKM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 212Pb-RMX-VH-PKM.